Biomea Fusion, Inc. Logo

Biomea Fusion, Inc.

Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.

BMEA | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1599 INDUSTRIAL ROAD, 94070 SAN CARLOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral covalent small molecules for the treatment of metabolic diseases and genetically defined cancers. The company's primary focus is on its metabolic franchise, advancing potential disease-modifying therapies for diabetes and obesity. Its lead clinical candidates include icovamenib (BMF-219), a covalent menin inhibitor being investigated for its potential to regenerate insulin-producing beta cells in patients with Type 1 and Type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist. The company's oncology pipeline features BMF-500, a covalent FLT3 inhibitor for acute leukemia. Biomea leverages its proprietary FUSION™ System to design its drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biomea Fusion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biomea Fusion, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biomea Fusion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America ACOG
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America ALMS
Alvotech Logo
Develops and manufactures affordable biosimilar medicines for patients worldwide.
United States of America ALVO
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.